NCT04395079View on ClinicalTrials.gov

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 7, 2020

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2026

Conditions
Metastatic Malignant Female Reproductive System NeoplasmPlatinum-Resistant Malignant Female Reproductive System NeoplasmRecurrent Malignant Female Reproductive System NeoplasmRefractory Malignant Female Reproductive System Neoplasm
Interventions
BIOLOGICAL

Durvalumab

Given IV

RADIATION

Internal Radiation Therapy

Undergo brachytherapy

BIOLOGICAL

Tremelimumab

Given IV

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER